Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
        OncoImmunology Volume 3 Issue 2
        Page e27680-
        
published_at 2014
            Title
        
        Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
        
        
    
                
                    Creators
                
                    Song Chang
                
                
            
            
                
                    Creators
                
                    Sadashivaiah Kavitha
                
                
            
            
                
                    Creators
                
                    Furusawa Aki
                
                
            
            
                
                    Creators
                
                    Davila Eduardo
                
                
            
            
            
                
                    Creators
                
                    Banerjee Arnob
                
                
            
    
        
            Languages
        
            eng
    
    
        
            Resource Type
        
        journal article
    
    
        
            Publishers
        
            Landes Bioscience
    
    
        
            Date Issued
        
        2014
    
    
        
            File Version
        
        Not Applicable (or Unknown)
    
    
        
            Access Rights
        
        metadata only access
    
    
            Relations
        
            
                
                
                [ISSN]2162-402X
            
            
                
                
                [PMID]info:pmid/24790793
            
            
            
                [isVersionOf]
                
                [URI]https://www.landesbioscience.com/journals/oncoimmunology/
            
    
        
            Schools
        
            大学院医学系研究科(医学)
    
                
